ALUR, trial summary

A randomised clinical trial investigating the effect of alectinib versus chemotherapy in ALK-positive NSCLC who have progressed on or are intolerant to crizotinib

        Z

NCT02604342    
2nd line crizotinib failure



Studied treatment
Control treatment chemotherapy (pemetrexed or docetaxel)



Patients ALK-positive NSCLC who have progressed on or are intolerant to crizotinib
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint PFS Design Parallel groups



EndpointX1N1X0N0TE95% CI OS - -9 - -9 no data PFS - -9 - -9 no data0,22,01,0

Links

press release

press release

ClinicalTrial.gov record NCT02604342



Registering number NCT02604342 (see trial on clinicaltrials.gov)
Code Name

 

All trials of alectinib

Appears in following systematic reviews: